Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Glide Pharmaceutical Technologies
Oxford (near), United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
The company successfully completed pre-clinical proof-of-concept studies with solid dose formulations of exenatide, octreotide, and teriparatide, showing bioequivalence to marketed liquid products[9].
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Solid dose formulations of therapeutics and vaccinespeptides
- Industry
- Biotech
02
Partnerships
Pfenex Inc. (anthrax vaccine)Cilian AG (influenza vaccine)Nypro
Beyond the preview
Go deeper on Glide Pharmaceutical Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glide Pharmaceutical Technologies.